Stock INCR INTERCURE LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

InterCure Ltd. Stock TEL AVIV STOCK EXCHANGE

Equities

INCR

IL0011063760

Healthcare Facilities & Services

Financials

Sales 2022 388.68 1.43K Sales 2023 355.55 1.31K Capitalization 211M 779M
Net income 2022 44M 162M Net income 2023 -62M -229M EV / Sales 2022 1,473,908 x
Net Debt 2022 22.37M 82.56M Net Debt 2023 94.35M 348M EV / Sales 2023 858,938 x
P/E ratio 2022
12.2 x
P/E ratio 2023
-3.41 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 60.24%
More Fundamentals * Assessed data

Chart InterCure Ltd.

Dynamic Chart

Latest news about InterCure Ltd.

InterCure Ltd. Provides Revenue Guidance for the Full Year 2024 CI
InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
InterCure Ltd. Provides Earnings Guidance for the Second Half and Full Year of 2023 CI
InterCure Ltd. Expects to Launch Its First Products in Germany in the Coming Months CI
InterCure Ltd. Announces Resignation of Rami Levy as Chief of Operations CI
InterCure Ltd. entered into a share purchase agreement to acquire Leon Pharm Ltd for ILS 8.3 million. CI
InterCure Ltd.(TASE:INCR) dropped from S&P Global BMI Index CI
InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Intercure to Delist Its Shares From the Toronto Stock Exchange MT
InterCure Provides Update About Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger MT
Transcript : InterCure Ltd., 2022 Earnings Call, Apr 04, 2023
InterCure Ltd. entered into an agreement to acquire 51% stake in Orni Pharmacy Ltd. CI
InterCure to Launch Trading on Nasdaq Wednesday MT
InterCure Ltd. Announces Earnings Results for the Second Quarter Ended June 30, 2021 CI
InterCure Provided Update on Its NASDAQ Listing MT
More news

Press releases InterCure Ltd.

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference BU
InterCure : Immediate Report PU
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million BU
InterCure : FORM 20-F For the fiscal year ended December 31, 2023 PU
InterCure : Announces FY2023 Result PU
More press releases

News in other languages on InterCure Ltd.

Tilray, Inc. : première exportation de cannabis vers Israël
More news

Managers and Directors - InterCure Ltd.

Managers TitleAgeSince
Alexander Rabinovitch CEO
 Chief Executive Officer 53 18-09-30
Amos Cohen DFI
 Director of Finance/CFO 45 20-02-29
Yisrael Gewirtz AUD
 Comptroller/Controller/Auditor 47 13-12-31
Members of the board TitleAgeSince
Ehud Barak CHM
 Chairman 81 18-08-31
Alexander Rabinovitch CEO
 Chief Executive Officer 53 18-09-30
Alon Shmuel Granot BRD
 Director/Board Member 62 20-10-31
More insiders

Company Profile

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
Sector
Healthcare Facilities & Services
Calendar
2024-08-11 - Q2 2024 Earnings Release (Projected)
More about the company

Sector Medical Farming

1st Jan change Capi.
CRUCIAL INNOVATIONS CORP. Stock Crucial Innovations Corp.
-.--% 339M
AYR WELLNESS INC. Stock Ayr Wellness Inc.
+23.87% 244M
ASCEND WELLNESS HOLDINGS, INC. Stock Ascend Wellness Holdings, Inc.
+8.25% 223M
ORGANIGRAM HOLDINGS INC. Stock Organigram Holdings Inc.
+40.70% 183M
JUSHI HOLDINGS INC. Stock Jushi Holdings Inc.
+33.76% 121M
IANTHUS CAPITAL HOLDINGS, INC. Stock iAnthus Capital Holdings, Inc.
-28.57% 121M
THE CANNABIST COMPANY HOLDINGS INC. Stock The Cannabist Company Holdings Inc.
-44.42% 114M
4FRONT VENTURES CORP. Stock 4Front Ventures Corp.
-7.69% 80.53M
BAKHU HOLDINGS, CORP. Stock Bakhu Holdings, Corp.
+100.00% 60.26M
Medical Farming
  1. Stock Market
  2. Equities
  3. INCR Stock
  4. INCR Stock